Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
16JUN

Nearly a billion mobilised, no cure

3 min read
10:26UTC

The Pandemic Fund activated up to 220.6 million dollars on 5 June; the US State Department committed 270 million bilaterally. Set against May's summit pledges, the mobilised aggregate approaches 990 million dollars.

ScienceDeveloping
Key takeaway

Close to a billion dollars is mobilised, but no licensed vaccine, treatment or rapid test exists.

The Pandemic Fund activated up to 220.6 million dollars in emergency grant financing on 5 June, behind a joint Africa CDC and WHO Continental Strategic Preparedness and Response Plan 1. The Pandemic Fund is the World Bank-hosted financing mechanism set up after Covid-19 to bankroll outbreak response. The US State Department committed a further 270 million dollars bilaterally as of 12 June, funding implementers such as International Medical Corps, which had screened more than 6,300 people and flagged 41 suspected cases for isolation 2.

Set against the roughly 500 million dollars pledged at the Africa CDC summit in May , the mobilised aggregate approaches 990 million dollars. The money has arrived faster than any vaccine, treatment or test, and the Pandemic Fund's own statement names why that is not the relief it sounds: no vaccine, no treatment and no rapid, reliable diagnostic exists for this virus.

That is the constraint cash cannot move. Emergency financing buys hospital beds, burial teams, fuel and field laboratories, but it cannot compress the regulatory clock on the treatment trial that only began this week, and it cannot conjure a bedside test that no one has built. The response has fixed its financing and shifted its binding constraint from money to the clinical pipeline, which runs on its own timetable.

Deep Analysis

In plain English

Nearly one billion dollars has been committed to fight this outbreak. That money comes from three main sources: the World Bank's Pandemic Fund, the US government, and pledges made at an Africa CDC summit in May. It pays for screeners, isolation units, contact tracers, transport, and supplies. But the Pandemic Fund's own statement names a stark problem: there is no approved vaccine, no approved drug, and no quick bedside test for this type of Ebola. The money can improve how well the response operates, but it cannot buy a pharmacological solution that does not yet exist. This is what outbreak economics looks like when preparedness R&D investment ran out before the pathogen emerged.

What could happen next?
  • Consequence

    The $270 million US bilateral commitment funds implementers including International Medical Corps, the same funders simultaneously maintaining the US entry ban on DRC, Uganda and South Sudan nationals (ID:4053), creating a foreign-policy contradiction visible to both the DRC government and the implementing organisations on the ground.

  • Risk

    Disbursement latency in the Pandemic Fund's FIF mechanism means some portion of the $220.6 million may not reach field implementers until late July, after the CDC model's August worst-case window has already opened.

First Reported In

Update #7 · Bundibugyo's fork stays open

US Department of State· 16 Jun 2026
Read original
Different Perspectives
Chinese health authorities
Chinese health authorities
China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.
US public health authorities
US public health authorities
CIDRAP and Dr Andrew Racine, president of the American Academy of Pediatrics, call 2026's 2,318 confirmed measles cases by 24 July the worst year since 1991's 2,126. Zero deaths against three in 2025 and a 7% hospitalisation rate, down from 11%, show record case counts have not brought record severity.
CEPI
CEPI
CEPI put an rVSV-platform vaccine candidate specific to Bundibugyo ebolavirus into trial-production on 31 July, developed by Hilleman Laboratories with MSD manufacturing and IAVI's reference virus, funded up to $8.5m. Eleven weeks into the third-largest Ebola outbreak on record, this is the first species-matched candidate; the licensed vaccine covers only Zaire ebolavirus.
Médecins Sans Frontières
Médecins Sans Frontières
MSF reports sexual-violence care in Ituri is almost non-existent, with 7 of 14 health centres closed or relocated by fighting, as Panzi Hospital logs 646 new survivors in six months, an 85% rise. Withdrawn US funding for post-exposure prophylaxis has left clinics across three provinces without PEP kits for months, a crisis running alongside Ebola, not caused by it.
DRC health workers at Elikya Ebola Treatment Centre
DRC health workers at Elikya Ebola Treatment Centre
Staff at DRC's Elikya Ebola Treatment Centre walked out on 25 July over unpaid wages, the second such action after Rwampara, while unconfirmed suspects occupy up to 64% of the country's isolation beds awaiting lab results. Workers are absorbing a response that has grown faster than its payroll and its labs.
Uganda's Ministry of Health
Uganda's Ministry of Health
Uganda's ministry says it discharged its last confirmed patient on 16 June, completed every contact's 21-day follow-up, and declared the country Ebola-free on 28 July, exactly 42 days later. It names Hon. Dr Chris Baryomunsi, Minister of Health, as overseeing a 20-case, 2-death outbreak it now considers closed.